JPMorgan Diversified Return International Eqty ETF vs Medtronic PLC — how do they compare? JPMorgan Diversified Return International Eqty ETF trades at $73.74, while Medtronic PLC trades at $82.31 (market cap $106.61B). The key difference: Medtronic PLC pays a 3.46% dividend while JPMorgan Diversified Return International Eqty ETF pays none, and JPMorgan Diversified Return International Eqty ETF is trading nearer its 52-week high, Medtronic PLC nearer its low. Which is the better fit depends on your goals.
| JPIN | MDT | |
|---|---|---|
52-Week High | $76.96 | $105.35 |
52-Week Low | $63.14 | $73.75 |
Market Cap | — | $106.61B |
Sector | — | Health |
Enterprise Value | — | $125.36B |
Dividend Yield | — | 3.46% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Medtronic (MDT) trades at $82.35, down 1.02% on the day, with a bullish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS expected at $1.39. Revenue grew to $33.54B in 2025, with a net income margin of 13.2%. Recent news highlights the acquisition of SPR and the launch of AI-powered surgical technology, signaling innovation-driven growth.
The outlook for MDT is positive, supported by analyst consensus with a $97.50 price target and 58% buy ratings. Key opportunities include robust cash flow and dividend stability, while risks involve rising debt levels and competitive pressures in medtech. The stock presents a value proposition with a P/E of 22.33, trading below the consensus target.
Trailing returns across standard periods
Latest headlines on both assets
The fund will invest at least 80% of its assets in securities included in the underlying index. The underlying index is comprised of equity securities across developed global markets (excluding North America) selected to represent a diversified set of factor characteristics.
Read more on JPIN →One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →